• Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing
• By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries
• Cybin filed the PCT application to provide broad international patent protection of key intellectual property

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to focus on its goal to improve the lives of those suffering from mental illness by changing the expectation of treatment. As part of that mission, the company has filed an international patent application that would provide the potential to obtain patent coverage in 153 countries (https://ibn.fm/Of5wi). “Technologies gained by Cybin resulting from our strategic acquisition of Adelia Therapeutics, coupled with subsequent research initiatives from our experienced scientific team, have produced Cybin’s first PCT (Patent Cooperation Treaty) filing,” said Cybin CEO Doug Drysdale. “As we progress our R&D and clinical programs, we expect to continue to create and develop innovative therapeutics with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects.” By filing a single international application with the Patent Cooperation Treaty (“PCT”), Cybin can simultaneously seek protection for its proprietary drug treatments in a large number of countries (https://ibn.fm/zTFMK). In addition, the PCT assists applicants in seeking patent protection internationally for their inventions, helps patent offices with their patent-granting decisions, and facilitates public access to a wealth of technical information relating to those inventions. Cybin filed the PCT application to provide broad international patent protection of key intellectual property in support of the company’s strategic objectives. Those objectives include the company’s three-pillar drug development strategy: creating a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; efficient drug delivery to enhance dosing control; and a potential novel treatment regimen. Specifically, the company is working on four drug programs: CYB001, a sublingual psilocybin formulation designed for patients suffering from major depressive disorder; CYB003 and CYB004, both proprietary deuterated psychedelic tryptamines designed for treatment of alcohol-use disorder and other therapy-resistant psychiatric disorders; and CYB005, a phenethylamine-targeting psychiatry and neurology treatment. Psychedelic therapies are being seriously considered as a novel treatment option for a variety of mental health issues. For decades, psychedelics have been largely ignored because both federal and state laws prohibited the substances. However, a growing body of research is showing evidence of both the efficacy and safety of psychedelic use, and public opinion about the drugs is changing. While psychedelics may feel like a new industry, they actually boast a long history of use within indigenous cultures that stretches back centuries. A paradigm shift has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, and Cybin is leading the way. Cybin is confident that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Highlights of Q1 report include quarter-over-quarter sales growth, cash and cash equivalents increase, successful $9 million capital raise
• SBEV beverage brand portfolio includes Salt Naturally Flavored Tequila, Copa Di Vino, Pulpoloco Sangria, TapouT Performance
• SBEV optimizes production, supply chain and distribution capabilities to accelerate brands that can be profitably exited for cash events

Splash Beverage Group (OTCQB: SBEV), a holding company with a leading portfolio of beverage brands, recently filed its Q1 2021 Report on Form 10-Q with the Securities and Exchange Commission (“SEC”) for the period ending March 31, 2021 (https://ibn.fm/skBFT). Highlights include rapid quarter-over-quarter sales growth, an increase in cash equivalents, and a successful $9 million capital raise earlier this year. SBEV’s report details the company’s successful sales performance throughout 2020 and early 2021, highlighted by a $2.3 million quarter-over-quarter increase from $112,003 in Q1 2020 to $2.4 million as of March 31, 2021. SBEV credits the increase primarily to the rollout of its vertically integrated B2B and B2C e-commerce Qplash distribution platform that sells goods on both Amazon and Shopify, along with increased sales from Copa Di Vino – its recently acquired single-serve wine business. SBEV’s cost of goods sold rose from $107,214 from Q1 2020 to $1,742,875 for the three months ended March 31, 2021. The company credits the $1,635,661 increase to the substantial growth in sales throughout the year. Cash and cash equivalents rose sharply from $380,000 on December 31, 2020 to $1,225,406 as of March 31, 2021. The company attributes this increase to cash received from its private placement memorandum (“PPM”) where 3,636,364 shares of company common stock were sold for $1.10 per share for aggregate gross proceeds of $4,000,000. As part of the PPM, each purchaser received a warrant to buy an additional share for every two shares purchased, resulting in a total of 3,637,065 total shares and warrants issued with gross proceeds of $4,000,771. SBEV also disclosed that it is now in a favorable financial position to pursue new opportunities following the successful completion of a $9 million capital raise in February 2021. According to the company, equity holders can no longer convert equity to debt as per a stipulation in the original merger agreement that stated equity-to-debt conversion would not be allowed if the $9 million capital raise was completed successfully. SBEV predicts increased momentum throughout 2021 and beyond. The company manages a portfolio of beverage brands with unique qualities that distinguish them from the competition – such as top-quality ingredients, distinctive packaging and health benefits. The company’s brands continue to trend favorably in their respective categories with products that include Salt Naturally Flavored Tequila, Copa Di Vino “wine by the glass,” TapoutT Performance, and Pulpoloco Sangria. The company’s growth strategy is defined by superior production methods, supply chain efficiencies and global distribution capabilities that are leveraged to rapidly develop and accelerate pre-existing brands that can be profitably exited for cash events. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

Date: June 22-23, 2021 SST/GMT+8 Time Zone Online Virtual Event Companies, start-ups, tech platforms, financial institutions, regulators, and investors are invited to attend the FinovateAsia 2021 on June 22-23, 2021, an online virtual event connecting global leaders redefining financial services. Finovate puts special emphasis on innovative technologies all set to shape the future of finance. The event offers companies to showcase interesting digital demos that demonstrate the use of technology such that these enterprises can secure more leads using their demos. Innovators, businesses, and finance experts can access this event digitally from anywhere in the world. The highlight of this event is that attendees avail presentations and case studies and attend the panel discussions. Further, businesses and start-ups can use the wonderful networking platform to make useful connections and collect resources. The event also offers its attendees an additional advantage, the seminar content will be available post-event on demand so that they can watch sessions in line with their schedule at times convenient to them. Highlights of FinovateAsia 2021 include:

• 500+ decision-makers and respected personnel from the VC’s, finance institutions, media, and more, of which 50% are from the finance background
• 50+ speakers and industry veterans who will share insights and opinions on policies that will shape the present and future of fintech
• Hundreds of meetings and panel discussions will be streamed digitally
• Post-event access to the event content
• A chance to demo your innovation/finance product in front of finance industry stalwarts

FinovateAsia is a global event that focuses on bringing the local fintech innovators to the center stage. Even in these uncertain times, FinovateAsia offers investors and finance persons the opportunity to network, connect, and discuss the challenges and the future policies from the comfort of your location, wherever you are in the world. The event commences with opening remarks from Greg Palmer, Vice President, Finovate. Attendees will be given a link to the digital platform two weeks before the event. They can make their profile and start connecting with other participants and arrange meetings. ConnectMe is FinovateAsia’s new virtual event platform that offers enhanced networking and interactive sessions. From group discussions to one-to-one chats, FinovateAsia gives participants the privilege to conduct digital meets at their preference and convenience. The networking option is open for a week after the event. For more details about the event and the discounts available, please visit https://ibn.fm/JPiyf

Date: June 23-24, 2021 Virtual Conference Medical Science Liaisons (“MSLs”), along with pharma companies and other life science professionals, are invited to attend DGE’S inaugural Next-Gen MSL Excellence Symposium being held on June 23-24, 2021. This symposium is the only virtual industry event to focus on the work challenges faced by MSLs, to emphasize the importance of their role in drug and device development and adapting to new technologies in the Post-COVID scenario. The event is hosted by Dynamic Global Events (“DGE”), a life science leader in organizing b2b events. The world-class event company is an industry leader meeting the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. MSLs are vital to the successful development of drugs and medical devices. They need to keep abreast with the latest research and development and adapt themselves to the evolving technologies, key to successful product utilization. The most important aspect of an MSL’s job is to maintain peer-to-peer relationships with KOLs (Key Opinion Leaders), meaning physicians, clinicians, and academic leaders at institutes, pharma companies, hospitals, and research centers. In addition, for the first time, a conference will focus on the pivotal role of MSLs and the work challenges faced by them. DGE’S Next-Gen MSL Excellence Symposium will offer a dynamic platform for the medical industry KOLs and decision-makers to come together and share their opinions and discuss the role of MSLs in the changing scenario. They will also offer valuable tips and techniques to build a successful MSL career and demonstrate the value of skills to the organization. The agenda of the Symposium includes the following discussion points:

• Improving the skills of MSL personnel for a successful career
• Utilizing business acumen, communication, and interpersonal skills to attain success
• Understanding the needs of an HCP and communicating complex scientific data effectively
• Avoiding burnout and managing work-life balances
• Impact of MSLs on the overall performance of an organization
• Engagement and collaboration with stakeholders and clinical development teams
• Managing virtual and hybrid engagements

This symposium also presents a wonderful opportunity for bright professionals working toward a lucrative MSL career. Medical Affairs professionals will interact with similar teams to learn new and expansive ideas and roles. To know more about the event, please visit https://ibn.fm/Zqhpr.

• Every series of BAND NFTs released will feature unique artwork and designs, being available for purchase only through the BAND NFT Marketplace
• The total number of BAND NFTs is anticipated to range between 9,000 and 12,000, stakeable for a minimum of 90 days and up to five years
• The entire BAND Royalty music catalog can be found on the company’s YouTube channel

The first series of BAND Royalty non-fungible tokens (“NFTs”) is a limited collection of 3,000 NFTs featuring one of 15 unique music blockchain art pieces. Each piece of art celebrates and showcases the diversity of the music industry, featuring talent, heritage, and various genres across the entire industry, and pricing begins at 1 ETH. As a music industry disruptor, BAND Royalty is the first to use NFTs to create the first-ever DeFi opportunity based on music royalties, providing a new way for fans to connect to their favorite music artists and share in their income, through royalties. The Series 1 NFTs were initially sold via OpenSea, the world’s largest NFT marketplace, but BAND has since switched gears and created its own first-ever music-only NFT marketplace, which can only be found on the company’s website at https://bandroyalty.com/buynfts. To gain access to the BAND Royalty NFT Marketplace, users must first connect a wallet. Vinyl and platinum NFTs are the only levels available for purchase at this time, as all three of the diamond-level NFTs have been sold. To make a purchase, users must have at least 1 ETH and gas in their wallet. While there are no guarantees on returns, BAND allows NFT holders to stake their NFT in one of three BAND Royalty Music Pools (“BRMP”). These BRMPs receive 50% of all royalty-streaming income from each track for each category. A percentage of what is left is used to grow the BAND royalty catalog. The three BRMPs available for staking include 1) publishing, 2) mechanical/public performance, and 3) synchronization. Staking does not equal ownership of the royalties but rather access to income from the available various royalty streams. Each BAND NFT must be staked for a minimum of 90 days to a maximum of 5 years. The longer the NFT is staked in a pool, the proportionally increased the amount of royalty shares. The NFTs are locked during the staking period, and any income earned will be calculated and held in reserve – awaiting completion of the staking period. Termination of the NFT staking before the allotted time will result in forfeiting all earnings, which will then be dispersed back to other stakers. The BAND Royalty music catalog includes songs performed by prominent artists, such as:

• Justin Timberlake – “Mirrors” – 827 million views on YouTube
• Beyonce – “Rocket” – 19.7 million views on YouTube
• Justin Timberlake ft. Jay-Z – “Murder HQ” – 500K views on YouTube
• Jane Zhang – “Dust My Shoulders” – 15 million views on YouTube
• Cher – “I Don’t Have to Sleep to Dream” – 58K views on YouTube

The BAND Royalty NFTs music catalog can be found on the BAND Royalty YouTube Channel, along with other interviews and additional informative videos. BAND plans to sell three more series of NFTs, each with 2,000 to 3,000 NFTs. Each of the series will be coupled with unique artwork and designs. The anticipated maximum capping for BAND NFTs falls between 9,000 and 12,000. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

• Social media engagement went up 87% for Instagram and 27% for Facebook, indicating a positive following for the Fan Pass platform overall
• The company’s 120-day strategy includes the release of version 2.0 of the Fan Pass platform, new company websites, paid media rollout and more
• Total artist sign-ups now surpassing 4,000 since launch, with app installs trending upward as well

Friendable (OTC: FDBL) has released growth metrics and performance totals for May 2021, highlighting an exponential increase across the board. The company reported the largest number of artist sign-ups to date, bringing the total to over 4,000 since the platform’s launch in July 2020. In May, Fan Pass added 1,452 new musicians to the live streaming artist platform – a 53% increase over April (https://ibn.fm/DEE1p). As Friendable prepares to release version 2.0 of the Fan Pass platform, the company notes other areas of success as it continues executing its 120-day strategy, which was announced recently. Social media engagement is a key indicator for Friendable’s management, with Instagram reach increasing 87% and Facebook’s increasing by 27%. All metrics and trends point to positive, overall brand recognition for Friendable’s live streaming music artist platform. Talking about the new Fan Pass version, Friendable CEO Robert A. Rositano Jr. said that “it’s time to unveil several new features to our artists, and we look forward to watching the artists’ revenues, along with the company’s steadily increase with this next version.” He also gave a little more background on the new offerings, as well as the reason for the company’s confidence in the upcoming developments. “These next several months are going to lead us to and eventually through our version 2 mobile and web app releases, which will include an entirely new suite of features, virtual currency options, automation and, ultimately, scale,” Rositano underlined. “It is our intent to grow our base, build our revenues and begin monetizing across the board, which we believe to be very achievable based on the results we have seen since our launch and every month following.” In April, Friendable initiated a signed Letter of Intent with Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) for the development of global entertainment and musical artist-driven non-fungible tokens (“NFTs”). Each Fan Pass artist NFT will represent a unique opportunity for new revenue streams for both artists and companies involved. The agreement between Friendable and Santo calls for creating a Fanpasscrypto Marketplace, which is expected to add a new offering to the company’s current artist offering and marketing strategies. The unique NFTs available through the marketplace will be digital and/or augmented reality NFT images. Each image may be of the specific entertainer or offer exclusive merchandising and interaction. These are only a few possibilities represented by the NFTs for the company to monetize and seek other opportunities with the brand and retail sponsors. It has been three years since the inception of Santo’s flagship crypto code SKULLYS, as explained by the company’s CEO Frank Yglesias (https://ibn.fm/GZ0oS). He also added, “we are proud to bring over 100,000 lines of unique code to the outstanding team over at Fan Pass. With the rise of blockchain and NFT technology, the future is only limited by our imagination.” Friendable believes that the incorporation of NFTs will increase the overall value through limited-edition releases, contingent upon availability and exclusivity. The company is currently exploring the possibility of incorporating special “Gold” or “Platinum” NFT tickets that could be used to unlock exciting opportunities, which may include options such as “Backstage VIP Pass” or “Exclusive Access” behind the scenes at a physical venue (not just a virtual one). For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• White label agreement with FLO Brands outlines launch of cannabis vape product line
• PULL beginning to execute strategy to get white label products into provincial dispensaries, drive up to $3 million of annual revenue
• Nikolaevsky reports that “white labeling has also begun to build momentum and gain sales traction for us”

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic industry, announced that it has finalized a white label agreement to launch a line of cannabis vape products (https://ibn.fm/MfSkc). The agreement was made between Pure Extracts’ wholly owned subsidiary, Pure Extracts Manufacturing Corp., and FLO Brands, based in Richmond, British Columbia. “We are excited about launching a white label product with our new partner, FLO Brands, a fellow BC company,” said Pure Extracts CEO Ben Nikolaevsky. “They have enormous capacity to create new cannabis products as the market matures here in Canada and consumer tastes evolve. With the addition of FLO and the increased capacity and flexibility our new cosolvent injection system provides, we have begun to execute our strategy with craft producers and branding specialists to get their white label products into the provincial dispensaries and drive up to $3 million of annual revenue from this vertical.” Pure Extracts’ strategy has been deliberate and careful with the end goal of becoming a premier white label product. Key steps included the completion of its all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The facility has been constructed to European Union GMP standards, allowing Pure Extracts to attract both domestic and export sales of products and formulations. In addition, the Company has applied for and been granted essential licenses by Health Canada. And late last year, the Company’s stock began trading on the Canadian Securities Exchange (“CSE”). In a recent corporate update (https://ibn.fm/cZea1), Nikolaevsky reported that “white labeling has also begun to build momentum and gain sales traction for us. We are in the final stages of bringing on two large Licensed Producers as customers in order to manufacture their cannabis 2.0 products in the vape and tincture sectors. Although the sales cycle has been longer with COVID-19, we are now regularly engaging with potential customer leads who are sending us a growing number of requests for information,” he said. “Our Pemberton, BC facility is fully operational and in daily production and readily able to meet the increasing demand for gummies, vapes and white label products.” FLO Brands represents the power Pure Extracts now has in the white label space. A boutique brand house focused on creating state-of-the-art, cannabis-based products featuring the finest genetics, Flo Brands is “excited to be partnering with Pure Extracts, a proven leader in the cannabis space, to launch our line of premium cannabis products and are very fortunate to have Ben and his team’s extensive experience on our side,” said FLO Brands CEO Joseph Ke. The collaboration between PULL and FLO initially calls for the production of 3 SKUs of 0.5 gram, 510 vape cartridges. In addition to its 30-plus proprietary formulations, Pure Extracts will be providing co-manufacturing services along with all sales and distribution including labelling, packaging, applying of excise stamps and shipping. Pure Extracts is a plant-based extraction company with a new vertical in functional mushrooms. The Company is positioned to be a dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products. The company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• HempFusion Wellness, Inc. is a health and wellness product marketer focused on hemp-derived cannabidiol (“CBD”) and probiotics
• The company has been making in-roads in significant markets worldwide, using its probiotics as an entry point for potential future CBD product access to marketplaces currently hesitant to permit CBD
• HempFusion recently announced that its Probulin probiotics products had been accepted for sale on Alibaba’s giant Tmall Global online marketplace throughout China, Hong Kong, Macau, and Taiwan, followed by conditional approval for selling some HempFusion CBD products there as well

Health and wellness supplement innovator HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) is advancing a visionary approach with a view to balancing people’s energy levels and general well-being by expanding its international distribution channels, demonstrating its compliance with regulatory standards for hemp-derived products worldwide while ferreting out access points for cannabidiol (“CBD”) in cannabis-wary outlets. HempFusion’s investment in meeting consumer health safety concerns has opened doors to major food and drug retail outlets and physician pipelines while many other CBD companies have searched for alternate entries into the competitive marketplace. The company’s HempFusion USA subsidiary, registered as HempFusion, Inc., provides consumers with a wide array of hemp-derived CBD products, including branded tinctures, capsules and products for sleep and stress. They also offer a full line of over-the-counter topicals designed to address, pain, eczema, acne and wound care.  Each of these OTC Drug listed products are formulated with a proprietary skin-nourishing and moisturizing base including Aloe vera, Shea butter, hemp extract derived omegas and CBD, botanical terpenes and other powerful botanicals.  The products are designed to serve performance athletes as well as the general public. HempFusion USA’s subsidiary Probulin Probiotics, LLC, produces a diverse group of scientifically formulated probiotic products that targets total gut health support, immune function support as well as probiotic extract based skin care for specific demographics to establish a competitive profile. The products provide help for consuming difficult-to-digest foods and for moisturizing and cleansing the skin, and some of them specifically are geared toward and women’s and children’s needs. The company’s products are sold in about 4,000 retail locations in all 50 U.S. states utilizing 45 brokers and sales representatives in the natural products industry and another 55 in the doctor/practitioner market, conventional food, drug, mass and convenience (“FDMC”) market and international markets, as well as the attention the company has received from its recent listings with the Toronto Securities Exchange (“TSX”) and the OTCQX markets. Probulin’s network for probiotics sales has proved useful for helping the company gain an entry point in marketplaces hesitant to consider CBD. For example, the company announce in March that Tmall Global, the world’s largest cross-border online marketplace with a reach of more than 750 million consumers in mainland China, Hong Kong, Macau and Taiwan, was permitting sales of Probulin’s Total Care Immune, Total Care, Daily Care, Women’s Health, Colon Support and My Little Bugs(TM) Total Care Probiotic For Kids (https://ibn.fm/fFfR3), and in April announced that Tmall has now conditionally approved, pending upcoming regulation changes in China,   HempFusion to sell its Acne Relief, Eczema Relief and Sports Pain Relief Creams, Pain Relief and Sports Pain Relief Balms, Pain Relief Gel and Wound Ointment products (https://ibn.fm/A3RfI). In the meantime, HempFusion continues to focus on other destinations within the Asian marketplace including Japan, Hong Kong and so on. HempFusion also sells its Probulin products in Mexico, South Korea and the United Arab Emirates, and Ireland with expectations of entering India and United Kingdom, where HempFusion’s CBD products may also reach consumer shelves. Probulin’s probiotics products are sold on Amazon, and although Amazon still does not allow CBD product sales HempFusion regards Probulin’s positioning as a potential quick-access point should Amazon change its policy regarding CBD sales. “COVID and continued lack of clarity from the FDA related to official regulatory guidance for CBD used in dietary supplements, foods and beverages has made 2020 a challenging year. However, these challenges have led to strategic changes, establishing the foundation for HempFusion to succeed in 2021 and beyond,” according to an April operational update by the company (https://ibn.fm/HstiE). For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• Robin Lawson – COO and co-founder, brings 13 years of experience in the iGaming industry to the team at Mobius Interactive Ltd.
• Having founded two VIP casino operations in Latin America, Lawson has delivered major gaming success in this lucrative, emerging market
• Lawson is actively steering the Mobius team toward fresh breakthoughs in the exciting and expanding international iGaming industry

In 2020, when the world was on lockdown, the international Esports community grew exponentially, with dramatic speed and volume. The team at Mobius Interactive were poised for action—they knew it was time to launch. In three months, Team Mobius created and produced three new and diverse brands around the globe: Mobius.bet , Club Double, and Aragon Casino, a record in iGaming development history. Collectively, Mobius delivers over 40 years of hands-on industry experience. This stellar team, operating with a revolutionary player journey/customer experience approach, has created a record-breaking company with Mobius Interactive. Chief Operating Officer and VP Robin Lawson, is a Mobius co-founder, bringing 13 years of industry experience to the table. Before Mobius, Lawson co-founded and served as COO of the startup Esports.com, which raised over $5.5m as a startup ICO in Germany. He was also a senior iGaming consultant for startup casinos and an advisor to blockchain-based tech groups. Robin’s long-time experience and proven track record with startup organizations demonstrate his powerful operational and leadership skills. Lawson describes Latin America and its expanding population of iGaming enthusiasts as a largely untapped market. Lawson has already found great success in this region. He previously founded two VIP casino operations in Latin America, including the European startup company, Tabella. Right now, Brazil is a top priority for COO Robin Lawson and the team at Mobius Interactive. Already established in Brazil, Mobius is crowning their Brazilian launch with a top sponsorship position: the FIFA World Cup Qualifying Matches. Soccer is the biggest sport in the world, and Brazil is a soccer powerhouse.  World Cup coverage in 2018 drew 3.6 billion viewers. All eight matches will be shown in Brazil on Globo TV, where the Mobius.bet brand will be prominently displayed to an average audience of 35 million viewers per game. The first match, Brazil vs Ecuador, is today, June 3. (https://ibn.fm/eOIk7). (https://ibn.fm/lTvG0). When it comes to overseeing the day-to-day administrative and operational functions at Mobius, Lawson believes in a dynamic, engaging approach. “I have learned from the experience of running multiple teams, in big organizations and startup scenarios, that when you give the team members responsibility, allowing them to set their own goals and KPIs for personal and professional growth, they work proactively to make a positive impact on the business. Happy staff, successful business! Mobius is on track to consolidate its brands in every region it enters worldwide. Before Mobius enters the US Market, the company will go public on several exchanges. The potential for growth in the US Market is high: sports gambling is legal in 22 states and 26 are currently seeking a route to legalization. Mobius Interactive is experiencing international growth and innovative success; they are a company to watch in 2021 and beyond. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Irina Nazarova, Brain Scientific’s marketing director, interviewed for Grit Daily, one of the top news hubs for startups, discussing exciting new product developments the company is working on
• BRSF is poised to extend the universe of EEG use cases, expanding possible markets for its disruptive products

Irina Nazarova, marketing director of Brain Scientific (OTCQB: BRSF), was interviewed for Grit Daily News, the top news source on Millennial and Gen Z startups, where she presented the latest work that the company does in the space of neurology medical devices (https://ibn.fm/CeYY3). Nazarova, who has significant marketing experience as the former Editor-in-Chief at the largest entertainment magazine in Russia, discussed with Daniela Elezovic of Grit Daily, the exciting neurological advancements made possible by the work of Brain Scientific and how the company works toward expanding what is possible in neurology space. Nazarova highlights products that the company has developed in the EEG space: NeuroCap, a ready-to-use and disposable EEG headset that allows any member of medical staff to perform routine EEG testing within minutes, and NeuroEEG, portable, wireless and miniature amplifier. NeuroCap aims to disrupt the current slow and cumbersome EEG testing and bring cost-effective yet high-quality alternatives in what Nazarova describes conservative industry. Traditionally, the use of EEG was limited to the medical or scientific settings where the device established itself as the gold standard for diagnosing conditions such as epilepsy. However, recent trends open the door for leveraging the power of the device beyond traditional settings to include applications related to our daily experiences such as in education, sleep, e-sports, meditation, and many more. The list of possible applications where EEG could be used is virtually limitless — it can improve any area of our lives. As Nazarova concludes, the technology does not have boundaries — and Brain Scientific continues to develop breakthroughs that enhance people’s lives. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF